Form 4: BIOCRYST Director Amy McKee Acquires Shares

BIOCRYST Pharmaceuticals Director Amy McKee acquired 783 shares of common stock at $7.18 per share as part of her board compensation.

Summary

• Amy E McKee, a Director of BIOCRYST PHARMACEUTICALS INC (BCRX), acquired 783 shares of common stock.
• The transaction occurred on November 28, 2025, with shares priced at $7.18 each.
• These shares were issued to Ms. McKee in lieu of 50% of her quarterly cash Board Member retainer, which amounts to $11,250.
• Following this acquisition, Ms. McKee directly beneficially owns 41,790 shares of BIOCRYST common stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director increasing their stake, even through compensation, generally signals alignment with shareholder interests. However, it's a routine transaction and not indicative of significant new information.

Positives

• Director Amy E McKee increased her direct beneficial ownership in BIOCRYST PHARMACEUTICALS INC by acquiring 783 shares.
• The acquisition of shares as part of compensation demonstrates alignment of the director's interests with those of shareholders.

Future Outlook

N/A. This filing reports a past transaction and does not contain forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• Acquisition of 783 shares of common stock by Director Amy E McKee as partial compensation for board services, valued at $7.18 per share.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director, even as compensation, can be viewed as a positive signal of management's alignment with shareholder interests.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of shares by a director as part of their compensation. While it shows alignment, it does not provide new fundamental information to alter an investment thesis or warrant a change in stock recommendation based solely on this filing.

Keywords

BIOCRYST PHARMACEUTICALS, BCRX, Form 4, Insider Transaction, Director Stock Acquisition, Equity Compensation, Amy E McKee